Go Deep
Orchid Pharma Limited
Orchid Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,765 | 636.0 | 3.32 | 0.28 | 1,023.95 |
| Oct 2026 | 22,047 | 611.1 | 3.19 | 0.28 | 983.95 |
Orchid Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3,041,713,000.0 | 2,376,073,000.0 | 2,072,670,000.0 | 1,935,242,000.0 |
| Net Profit | 32,244,000.0 | 237,802,000.0 | -126,135,000.0 | -57,236,000.0 |
| EPS | 0.5 | 4.7 | -2.5 | -1.1 |
Orchid Pharma Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 12,171,742,000.0 | 13,886,881,000.0 | 8,190,663,000.0 | 6,658,984,000.0 |
| Net Profit | 99,591,000.0 | 1,350,705,000.0 | 921,665,000.0 | 463,183,000.0 |
| EPS | 1.7 | 22.6 | 19.1 | 11.3 |
Orchid Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 22,584,277,000.0 | 20,773,655,000.0 | 15,538,739,000.0 | 12,252,063,000.0 | — |
| Total Liabilities | 6,941,207,000.0 | 5,234,336,000.0 | 3,844,078,000.0 | 5,365,573,000.0 | — |
| Total Equity | 15,643,070,000.0 | 15,539,319,000.0 | 11,694,661,000.0 | 6,886,490,000.0 | — |
Owes vs Owns
Orchid Pharma Limited owed ₹0.31 for every ₹1 it owned in Mar 2026, down from ₹0.44 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.31× | 0.25× | 0.25× | 0.44× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Orchid Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Receivables 16.9%Inventory 16.5%Fixed assets (tangible) 49.7%Intangible assets 3.3%Long-term investments 2.4%Other assets 11.0%
How it's funded — Mar 2026
Short-term debt 5.2%Long-term debt 8.2%Payables 15.4%Other liabilities 2.0%Shareholders' equity 69.3%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 7.1 | 21.2 | 4.5 | 27.5 |
| Receivables | 381.4 | 353.1 | 195.5 | 215.2 |
| Inventory | 372.3 | 457.3 | 149.4 | 228.7 |
| Fixed assets (tangible) | 1,122.0 | 833.6 | 645.1 | 621.2 |
| Intangible assets | 73.7 | 17.0 | 14.9 | 0.4 |
| Long-term investments | 53.8 | 50.4 | 36.9 | 44.4 |
| Other assets | 248.2 | 344.8 | 507.5 | 87.7 |
| Liabilities & equity | ||||
| Short-term debt | 116.7 | 143.3 | 14.0 | 182.5 |
| Long-term debt | 184.7 | 10.0 | 120.4 | 148.8 |
| Payables | 346.7 | 336.2 | 229.6 | 174.4 |
| Other liabilities | 46.0 | 33.9 | 20.4 | 30.8 |
| Shareholders' equity | 1,564.3 | 1,553.9 | 1,169.5 | 688.6 |
| Net tangible assets | 1,490.6 | 1,536.9 | 1,154.5 | 688.3 |
Orchid Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 1,256,373,000.0 | 513,707,000.0 | 1,259,920,000.0 | 183,380,000.0 | — |
| Investing Activities | -2,768,795,000.0 | -364,834,000.0 | -3,120,286,000.0 | -312,139,000.0 | — |
| Financing Activities | 1,371,375,000.0 | 24,573,000.0 | 1,670,404,000.0 | 311,664,000.0 | — |